Overview

• US biopharmaceutical firm's Q4 net loss narrowed yr/yr

• Lower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024

Outlook

• Monopar plans to submit NDA for ALXN1840 to FDA in mid-2026

• Company expects current funds to support operations through at least Dec 31, 2027

Result Drivers

• LOWER R&D EXPENSES - Q4 R&D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yr

• HIGHER G&A EXPENSES - Q4 G&A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal fees

Company press release: ID:nGNX9rJKMz

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Monopar Therapeutics Inc is $112.00, about 105.3% above its March 26 closing price of $54.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)